hero-inner-2

Our Science

About SLC Transporters

SLC transporters are fundamental regulators of human biology that have never been systematically addressed in drug development – until now.

SLCs, or metabolite transporters, are an ancient family of proteins. They are the gatekeepers for metabolites, which serve as the language of cellular communication. As regulators of the location of hundreds of metabolites, SLCs play a crucial role in health and disease, including modulating gut homeostasis and immunometabolism.

HISTORY OF SLCs IN DRUG DEVELOPMENT

Serotonin transporter

JNANA’S PLATFORM

At the core of our platform is a deep and comprehensive effort to understand – inside and out – the SLC transporter family and unlock an entirely new frontier of druggable targets.

OUR APPROACH

photo-02

Knowledge of human disease biology

We delve deeply into disease pathways. We integrate knowledge of human disease biology, including genetics, tissue and single-cell gene expression, metabolite pathways and CRISPR functional screens to validate previously undiscovered targets within the SLC transporter family.

photo-03

Hit generation

We have developed an innovative drug discovery platform — including a proprietary set of tools and assays we call RAPID — to efficiently generate functional hits. This early access to tool compounds opens up a more direct route to pharmacologically validate new targets and generate leads.

Molecules

Small molecule drugs

We focus on small molecules because of their versatility in modulating transporters in numerous ways: through inhibition, activation and protein homeostasis, and by binding to both substrate and allosteric sites. No other modality has as well-trodden a path through development and manufacturing.

AREAS OF IMPACT: IBD AND BEYOND

Inflammatory Bowel Disease
We are focused on advancing differentiated therapeutics for Crohn’s disease and ulcerative colitis that act by modulating gut barrier function or innate immune pathways.

Broadening the impact
In parallel, we are pursuing therapeutics modulating novel SLC transporter targets in other diseases of great unmet need, including first-in-class therapies for currently untreated monogenic neurological diseases.